stat3

STAT3-IN-3 is a potent and selective signal transducer inhibitor and transcription 3 (STAT3) activator.

STAT3-IN-B9 (B9) is an inhibitor of abnormal STAT3 activation and inhibits the proliferation of tumor cells including MDA-MB-468, MDA-MB-231, and DU145.

JAK2/STAT3-IN-1 is a GP130 inhibitor with anti-tumor effects and can be used to study inflammation, autoimmunity and cancer.

(R)-JAK2/STAT3-IN-10a is the R-isomer of JAK2/STAT3-IN-1.JAK2/STAT3-IN-1 is a GP130 D1 structural domain inhibitor with antitumor activity that inhibits the phosphorylation of JAK2 and STAT3. The KD value of (R)-JAK2/STAT3-IN-1 on GP130 protein is 3.8 μM.

STAT3 Degrader-2 is a PROTAC-based compound that effectively reduces the total STAT3 protein levels, and is utilized in the research of cancer and various diseases [1].

PROTAC STAT3 degrader-2 is a selective and efficacious PROTAC degrader of STAT3 protein with a DC 50 of 3.54 μM in Molm-16 Cell. PROTAC STAT3 degrader-2 has the potential for cancer research [1] .

STAT3 Degrader-1 (Compound 295) is a potent degrader of STAT3, utilized in anticancer research [1].

STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .

STAT3-IN-12 is a potent inhibitor of STAT3 signalling and inhibits IL-6-induced activation of the JAK/STAT3 signalling pathway. STAT3-IN-12 inhibits the growth and migration of cancer cells, blocks the cell cycle and induces apoptosis. HCC), oesophageal cancer.)

STAT3-IN-13 is a potent STAT3 inhibitor.STAT3-IN-13 has antiproliferative and anticancer activity and acts by binding to the structural domain of STAT3 SH2.STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705, which induces apoptosis and inhibits tumor cell growth and metastasis.STAT3-IN-13 can be used to study breast cancer and liver cancer. The study of breast cancer and hepatocellular carcinoma.

α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM). α7 nAchR-JAK2-STAT3 agonist 1 has been shown to have a positive effect on iNOS, IL-1β and IL-1β in murine macrophages RAW264.7. α7 nAchR-JAK2-STAT3 agonist 1 was effective in inhibiting the expression of iNOS, IL-1β and IL-6 in mouse macrophages. α7 nAchR-JAK2-STAT3 agonist 1 inhibited LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 agonist 1 was able to be used to study sepsis.

Stat3 (124H6) Mouse mAb #9139M is a useful organic compound for research related to life sciences and the catalog number is T64573.

STAT3-IN-1 selective and orally active inhibitor of STAT3(in HT29 and MDA-MB 231 cells, with IC50 values of 1.82 μM and 2.14 μM , respectively), induces tumor apoptosis.

STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and exhibits anti-proliferative properties. It promotes apoptosis by activating caspase-3 and elevating levels of cleaved polyADP-ribose polymerase, in addition to enhancing maturation and antigen presentation in dendritic cells. Moreover, STAT3-IN-18 has demonstrated in vivo safety.

STAT3-IN-20 (Compound 40), with an IC50 of 0.65 μM, is a selective inhibitor targeting the SH2 domain of STAT3, thereby impeding its phosphorylation, nuclear translocation, and subsequent gene transcription. The compound demonstrates antiproliferative effects on DU145 and MDA-MB-231 cancer cell lines, which have overactivated STAT3, with IC50 values of 2.97 μM and 3.26 μM, respectively. Moreover, STAT3-IN-20 induces cell cycle arrest and apoptosis [1].

STAT3-IN-10 (A11) is an inhibitor of STAT3 that directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces apoptosis in cancer cells (IC 50 = 5.18 μM) [1].

STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.

STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1].

STAT3-IN-11 is a selective STAT3 inhibitor with inhibitory effects on phosphorylation of the STAT3pTyr705 site and phosphorylation of Survivin.STAT3-IN-11 promotes apoptosis in cancer cells and is a candidate compound for the treatment of cancer.

STAT3-IN-9, a potent inhibitor of STAT3 activation at Tyr705, exhibits no impact on the phosphorylation of STAT1 at Tyr 701. Additionally, this compound efficiently induces apoptosis and cell cycle arrest specifically at the G2/M phase [1].

STAT3-IN-15, a potent and orally active inhibitor targeting STAT3, effectively combats idiopathic pulmonary fibrosis (IPF) by hindering STAT3 phosphorylation. Additionally, it impedes TGF-β1-induced migration and deformation of epithelial cells and prevents epithelial-mesenchymal transition (EMT), offering a multifaceted approach against IPF.

STAT3-IN-A69 is an inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo.

Phospho-Stat3 (Tyr705) Antibody #9131R is a useful organic compound for research related to life sciences and the catalog number is T64629.

Stattic (STAT3 Inhibitor V) is a STAT3 inhibitor (IC50=5.1 μM) that selectively inhibits STAT3 activation, dimerization, and nuclear translocation. Stattic has antitumor activity and induces apoptosis.

C188 is a cell-permeable naphthol compound and a STAT3 inhibitor. C188 inhibits IL-6-stimulated STAT3 Tyr705 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket, while exhibiting little effect agai

Alantolactone (Inula camphor)(Alant camphor), a sesquiterpene lactone, has potential activity against triple-negative breast Y MDA-MB-231 cells by suppressing the signal transducer and activator of transcription 3 (STAT3) signaling pathway.

Butein (2’,3,4,4’-tetrahydroxy Chalcone), a plant polyphenol, is isolated from Rhus verniciflua. It can inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, and also can inhibit EGFR.

APTSTAT3-9R acetate is a selective peptide binding STAT3 with antiproliferative and antitumor activity. APTSTAT3-9R acetate and inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation.

Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.

Triacetylresveratrol (Acetyl-trans-resveratrol) has anti-cancer activity,it inhibits the phosphorylation of STAT3 and NFκB, down-regulates Mcl-1, and up-regulates Bim and Puma in pancreatic cancer cells.

Nifuroxazide (Diarlidan) is an orally available and cell-permeable nitrofuran-based antidiarrheal agent. It has the inhibitory effect against the activation of cellular STAT1/3/5 transcription.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

Lenalidomide-Br is an analog of the cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, which is used in the recruitment of CRBN proteins. It is able to utilize linkers to attach to protein ligands to form PROTACs such as the PROTAC STAT3 degrader SD-36.

JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.

inS3-54-A26 is an inhibitor of the DNA-binding domain of STAT3. inS3-54-A26 suppresses tumor growth, metastasis and the gene expression of STAT3.

Nitroaspirin (NCX 4016) is a nitric oxide donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin induces significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins. Nitroaspirin has antithrombotic and antiplatelet properties and acts as a direct and irreversible inhibitor of COX-1.

ML116 is a potent and selective STAT3 inhibitor.

MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.

Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials.

SD-36 is a selective and efficient STAT3 protein degrader (Kd=~50 nM) with antitumor activity that promotes growth inhibition and induces apoptosis by inhibiting Mcl-1 in gliomas.SD-36 inhibits the transcriptional activity of STAT3.

SC-2001 is a MCL-1 inhibitor. SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellu

STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.

ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.

APTSTAT3-9R-9R is a STAT3 inhibitor (Ki: 231 nmol/L). STAT3 has been reported to promote the proliferation, survival, metastasis, immune escape, as well as drug resistance of cancer cells, making it a promising target for various diseases. However, though

C188-9 (TTI-101) is a Stat3 inhibitor with an IC50 of 4-7 μM.

BP-1-102 is an orally active, effective and specific STAT3 inhibitor. BP-1-102 binds Stat3 (Kd: 504 nM), then blocks Stat3-phosphotyrosine (pTyr) peptide interactions and Stat3 activation (4-6.8 μM), and selectively inhibits migration, survival, growth, and invasion of Stat3-dependent tumor cells. The BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Bcl-xL, Cyclin D1, Survivin, and VEGF.

Ochromycinone (STA 21) is a selective STAT3 inhibitor.

Scutellarin (Scutellarein-7-glucuronide), an active flavone isolated from Scutellaria baicalensis, can inhibit RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts, and down-regulate the STAT3 Girdin Akt signaling in HCC cells.

HJC0152 hydrochloride (HJC0152) is a signal transducer and activator of transcription 3 (STAT3) inhibitor.

1. Atractylenolide-I has an anti-inflammatory effect by inhibiting TNF-α and IL-6 production; ameliorates sepsis syndrome, liver and kidney functions by reduction of pro-inflammatory cytokines and LPS. 2. Atractylenolide-I significantly sensitizes the res